CXCL9 and neoplasm: In pretreatment tumor tissue, response to nivolumab and ipilimumab correlated with higher messenger RNA (mRNA) expression of CXCL9 (P = 0.011) (Fig. 3 A), consistent with reported results in multiple tumor types (Litchfield et al., 2021).